Callio Therapeutics Aims To Overcome Enhertu Resistance With Multi-Payload ADCs

 
• By Andrew McConaghie

The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.

Singapore (Prasit Rodphan/Shutterstock.com)
Callio Therapeutics is based in Singapore and Seattle. • Source: Shutterstock

More from Start-Ups & SMEs

More from Financing